Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
Publication year
2022Source
European Urology Oncology, 5, 5, (2022), pp. 553-563ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Urology
Journal title
European Urology Oncology
Volume
vol. 5
Issue
iss. 5
Page start
p. 553
Page end
p. 563
Subject
Radboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life Sciences; Radboud University Medical Center; Urology - Radboud University Medical CenterThis item appears in the following Collection(s)
- Academic publications [243984]
- Electronic publications [130695]
- Faculty of Medical Sciences [92811]
- Open Access publications [104974]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.